Cardiovascular System: Blood - PowerPoint Presentation

Cardiovascular System: Blood Clinical Anatomy Tony Serino, Ph.D .

Blood: Topic Objectives Be able to describe the physical properties of the blood including its components. Be able to explain how blood cells develop and what key ingredients are necessary in RBC development. Understand hemoglobin structure and the effect of a point mutation. Understand the molecular basis of blood typing and be able to interpret blood typing tests results. Be able to apply blood types in transfusions and list their abundance. Be able to describe the characteristics of WBC types and their abundance, be able to use differential WBC count data to interpret selected clinical diagnosis. Be able to describe platelet formation and their characteristics and functions. Be able to describe hemostatic reflexes and the clotting process Be able to explain the results of bleeding and clotting tests and the types of bleeding disorders.

Blood Liquid connective tissue Arises from hemopoietic tissue: 1. myeloid tissues (Red bone marrow) 2.lymphoid tissues (thymus, spleen, lymph nodes, tonsils, etc. In fetus, liver and yolk sac are hemopoietic

Properties of the Blood Volume 4-6L (5-6L men, 4-5L women) based on body size (8% of total body weight) pH 7.4 + 0.1 5X the viscosity of water Hematocrit = 45

Blood Composition

Plasma Composition 90% water 10% suspended or dissolved constituents Plasma Constituents (10%) 0.9% NaCl + other electrolytes Nutrients Plasma proteins: albumin, globulins, fibrinogen Dissolved gases: O 2 , CO 2, N2

Functions of the Blood Transportation media Osmoregulation Acid-Base balance Protection

Hemopoiesis (RBC development) Rate controlled by erythropoietin secretion Availability of Fe ++ , folic acid, vitamin B12 and amino acid precursors for hemoglobin production

RBC Production Control

Formed Elements

RBC (erythrocyte) Lives 120 days Non-nucleated biconcave disc 4.5-5.5 million/mm 3 1/3 of cytoplasm is hemoglobin

Rouleau

Hemoglobin

Hemoglobin Metabolism

Point Mutation in Sickle Cell

Sickle Cell Anemia

Blood Types

Blood Typing Anti-D

ABO Blood Group Summary

WBC Development

WBC Development

Distribution of WBC

Neutrophil Most abundant circulating WBC (55-65% of WBCs), highly phagocytic, 1 st to arrive at site of infection

Eosinophil 2-4% of WBC, combat irritants that trigger inflammation, phagocytic for Ag-Ab complexes, destroy worm infections, limit inflammation

Basophil Least abundant WBC (0.5% of WBC), trigger inflammation, contain vesicles with vasoactive compounds

Monocyte 3-8% of WBC, highly phagocytic and chemotaxic, arrive second to neutrophils at site of infection but in more massive numbers, can undergo diapedesis; some take up permanent residence in some tissues (often has a C-shaped nucleus)

Lymphocyte Second most abundant WBC (20-30% of WBC), function in specific immunity, two types: T and B cells

Platelet Development

Platelets 150-400 thousand/mm 3 2-4 mcm in diameter Function in clotting and vessel repair

Hemostasis (stoppage of bleeding) Extravascular Mechanisms Tightening of skin and muscles around injury Behavior response (elevate, applied pressure) Vascular Mechanisms Vasoconstriction (vascular spasms) Intravascular Mechanisms Platelets –plug formation and factor secretion (PF 3 ) Clotting factors (extrinsic and intrinsic system)

Platelet Plug and Clotting The common clotting pathway Platelet aggregation is increased by the stuck platelets releasing Thromboxane which stimulates vasoconstriction and attracts more platelets to area. Prostacyclin inhibits this and is released by non-damaged endothelial cells

Platelet stimulated (PF 3 ) (TF) (PF 3 ) or (TF) (Stabilizing Factor)

Coagulation Summary Coagulation may be triggered by intrinsic or extrinsic pathway, but in the body the extrinsic path is the one most commonly used. Activated Factors X, V, Ca 2+ , and PF 3 or TF combine to change Xa into prothrombin activator which catalyzes prothrombin to thrombin Thrombin then catalyzes Fibrinogen to Fibrin turning the blood into a gel-like state Activate Factor XIII stabilizes and strengthens the fibrin. Finally the platelets in the clot contract, squeezing the plasma from the clot. (Clot retraction) After 2 days, enzymes in clot activate plasminogen into plasmin with begins dissolving clot

Fibrin Clot

Bleeding and Coagulation Tests Bleeding time –the time it takes a small wound to stop bleeding Coagulation (clotting) time –the time it takes to form a blood to clot in a test tube (test intrinsic system) but not that sensitive Thrombin time –measures the time for blood to clot in a tube when thrombin is added Prothrombin time (pro-time, PT) –evaluates the extrinsic mechanism Partial Thromboplastin time (PTT) –tests the intrinsic system, more sensitive than clotting time

Bleeding Disorders Thrombocytopenia –decrease number of platelets Impaired Liver Function responsible for many of the clotting factors in the blood Vit. K used as co-factor in many clotting factor syntheses; liver bile salts help in absorbing this vitamin Hemophilia –hereditary bleeding disorders Class A (classical) –deficiency of factor VIII; most common hemophilia (83%) Class B deficiency of factor IX A & B is sex (X) linked trait; mainly seen in males Class C deficiency of factor XI –less severe; seen in both sexes